Home › Funds › Stonepine Capital Management, LLC › XFOR
Stonepine Capital Management, LLC position in XFOR
X4 PHARMACEUTICALS INC · Health Care
Stonepine Capital Management, LLC reported holding 224,989 shares of XFOR (X4 PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$1.1M, representing 0.69% of its reported portfolio and ranking #35 among its reported holdings. Stonepine Capital Management, LLC has disclosed XFOR holdings in 5 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Stonepine Capital Management, LLC's XFOR position evolved
Stonepine Capital Management, LLC first disclosed a stake in XFOR in Q3 2023 at 5,273,685 shares (US$5.7M). Across 5 filings, Stonepine Capital Management, LLC increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 224,989 shares valued at US$1.1M — a reduction of -110,320 shares quarter over quarter.. Notable position changes include a 44% trim in Q4 2025 (shares rose 3% over the following quarter), a 44% trim in Q1 2026 (shares rose 13% over the following quarter), a 33% trim in Q2 2026 (shares fell 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.27M | $5.75M | New |
| Q3 2025 | 1.06M | $3.61M | New |
| Q4 2025 | 593.57K | $2.37M | Reduce |
| Q1 2026 | 335.31K | $1.38M | Reduce |
| Q2 2026 | 224.99K | $1.05M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XFOR and 13F data
XFOR (X4 PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in XFOR — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$37.2M), PERCEPTIVE ADVISORS LLC (US$37.0M), Saturn V Capital Management LP (US$32.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XFOR
- Bain Capital Life Sciences Investors, LLC 7.97M sh · $37.21M · Q2 2026
- PERCEPTIVE ADVISORS LLC 7.93M sh · $37.05M · Q2 2026
- Saturn V Capital Management LP 6.97M sh · $32.57M · Q2 2026
- Empery Asset Management, LP 6.93M sh · $32.37M · Q2 2026
- Deep Track Capital, LP 5.88M sh · $27.45M · Q2 2026
- Kalehua Capital Management LLC 3.72M sh · $17.39M · Q2 2026
- NEA Management Company, LLC 3.23M sh · $15.10M · Q2 2026
- Rosalind Advisors, Inc. 3.21M sh · $15.01M · Q2 2026
- Trails Edge Capital Partners, LP 2.57M sh · $12.01M · Q2 2026
- BVF INC/IL 2.23M sh · $10.43M · Q2 2026
- Venrock Adviser, LLC 1.93M sh · $9.03M · Q2 2026
- Samsara BioCapital, LLC 1.40M sh · $6.52M · Q2 2026
More on Stonepine Capital Management, LLC
FAQ
How long has Stonepine Capital Management, LLC held XFOR?
Stonepine Capital Management, LLC has disclosed XFOR holdings in 5 of the last 12 reported quarters, going back to Q3 2023.
What is Stonepine Capital Management, LLC's current position in XFOR?
As of Q2 2026, Stonepine Capital Management, LLC holds 224.99K shares of XFOR (X4 PHARMACEUTICALS INC), valued at $1.05M, representing 0.69% of its reported portfolio and ranking #35.
Has Stonepine Capital Management, LLC been buying or selling XFOR?
In the latest 13F filing (Q2 2026), Stonepine Capital Management, LLC reduced its position in XFOR.
Which other funds hold XFOR?
Other major institutional holders of XFOR include Bain Capital Life Sciences Investors, LLC, PERCEPTIVE ADVISORS LLC, Saturn V Capital Management LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.